| Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories |
The
following table presents reportable segment profit and loss, including significant expense categories, attributable to our reportable
segment for the three months ended March 31, 2026 and 2025:
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories
| |
|
2025 |
|
|
2025 |
|
| |
|
Three months ended March 31, |
|
| |
|
2026 |
|
|
2025 |
|
| Preclinical, clinical trial and other costs |
|
$ |
1,423,041 |
|
|
$ |
1,197,035 |
|
| Research and development personnel expense(1) |
|
|
386,168 |
|
|
|
391,505 |
|
| General and administrative personnel expense(2) |
|
|
676,382 |
|
|
|
673,779 |
|
| Administrative and facilities expense(3) |
|
|
845,623 |
|
|
|
584,671 |
|
| Other income, net(4) |
|
|
45,965 |
|
|
|
(12,585 |
) |
| Total |
|
$ |
3,377,179 |
|
|
$ |
2,834,405 |
|
| Net loss |
|
$ |
3,377,179 |
|
|
$ |
2,834,405 |
|
| (1) |
|
Research
and development personnel costs include employee stock-based compensation expense of $17,144 and $46,720 for the three months ended
March 31, 2026 and 2025, respectively. |
| (2) |
|
General
and administrative personnel costs include employee stock-based compensation expense of $52,387 and $122,655 for the three months
ended March 31, 2026 and 2025, respectively, and are net of reimbursements received from CorLyst, LLC. |
| (3) |
|
Administrative
& facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel,
and other administrative costs. |
| (4) |
|
Other
income, net consists of interest and dividend income, unrealized loss on our digital asset, and other miscellaneous income. |
|